Cat3

📢 Excited to share our latest publication in Scientific Reports! Our study highlights a key but often overlooked factor in cancer immunotherapy: the route of administration. Using preclinical models of lung cancer, we show that delivering immunomodulatory agents directly to the airways can: ✅ Reduce systemic inflammation and toxicity compared with intravenous administration ✅Enhance local anti-tumor immune responses ✅ Increase infiltration of effector T cells in the lungs ✅ Improve tumor control These findings support the development of locally delivered immunotherapies as a promising strategy to improve the efficacy and safety of lung cancer treatments. A big thank you to all co-authors from CEPR INSERM Lab and collaborators who contributed to this work! 🙏 📖 Read the full article here: https://www.nature.com/articles/s41598-026-58254-y #LungCancer #Immunotherapy #DrugDelivery #Immunology #ScientificReports Inserm Grand Ouest Université de Tours CHRU de Tours

😊 Very proud to share our new article published in the prestigious The Lancet Respiratory Medicine journal! 🎓 In this work, we developed a parsimonious machine-learning tool to define and quantify immune dysregulation, supporting a more biologically informed approach to immunomodulation.This approach has the potential to improve prognostication, enhance the evaluation of treatment responses, and identify patients most likely to benefit from targeted immunomodulatory therapies. CEPR INSERM LabUniversité de ToursInserm Grand Ouesthashtag#immunomodulation hashtag#machine-learning hashtag#clinical data https://www.sciencedirect.com/science/article/pii/S2213260025004291  

Guillaume was appointed president by the general assembly of the French Society of Medical Mycology (SFMM) for the next four years.